Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 2,307,831 shares, a growth of 33.1% from the December 31st total of 1,733,403 shares. Based on an average daily volume of 1,930,381 shares, the short-interest ratio is currently 1.2 days. Currently, 4.1% of the shares of the stock are short sold. Currently, 4.1% of the shares of the stock are short sold. Based on an average daily volume of 1,930,381 shares, the short-interest ratio is currently 1.2 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Pyxis Oncology by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after buying an additional 14,566 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Pyxis Oncology by 2,690.9% in the third quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after acquiring an additional 593,853 shares during the period. Longaeva Partners L.P. bought a new stake in Pyxis Oncology in the third quarter valued at approximately $1,117,000. Citadel Advisors LLC acquired a new stake in Pyxis Oncology during the 3rd quarter valued at approximately $749,000. Finally, Jane Street Group LLC bought a new position in Pyxis Oncology during the 2nd quarter worth approximately $370,000. 39.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PYXS. Zacks Research lowered Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Royal Bank Of Canada decreased their target price on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. HC Wainwright raised their price target on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, Guggenheim lifted their price target on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pyxis Oncology currently has an average rating of “Moderate Buy” and an average price target of $7.20.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $1.49 on Wednesday. The company has a 50 day simple moving average of $2.41 and a 200 day simple moving average of $2.46. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.55. The firm has a market cap of $92.77 million, a PE ratio of -0.93 and a beta of 1.45.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, research analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.